Pregled bibliografske jedinice broj: 33997
Treatment of Tension-Type Headache by Injection of Botulinum toxin Type A: Double-blind placebo-Controlled Study
Treatment of Tension-Type Headache by Injection of Botulinum toxin Type A: Double-blind placebo-Controlled Study // American Academy of Neurology 51st Annual Meeting / xx (ur.).
Toronto: Lippincott Williams and Wilkins, 1999. (ostalo, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 33997 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Treatment of Tension-Type Headache by Injection of Botulinum toxin Type A: Double-blind placebo-Controlled Study
Autori
Relja, Maja ; Koršić, Marta
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
American Academy of Neurology 51st Annual Meeting
/ Xx - Toronto : Lippincott Williams and Wilkins, 1999
Skup
American Academy of Neurology 51st Annual Meeting
Mjesto i datum
Toronto, Kanada, 17.04.1999. - 24.04.1999
Vrsta sudjelovanja
Ostalo
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Tension-type headache; botulinum toxin
Sažetak
The objective was to evaluate the safety and efficacy of botulinum toxin A injections in the treatment of patients with chronic tension type headaches (TTH). BTX-A was compared with placebo with TTH. We investigate 16 patients with TTH (F/M=9/7, age range 23-64 years) through 8 weeks double.blind, cross over, placebo controlled study. BTX-A and/or placebo were injected in the most tender pericranial muscle.Tendernes was evaluated by manual palpation in the frontalis, trapezius and sternocleidomastoideus muscles. The tenderness assessment (scale 0-3) was performed at bazeline and 1, 2, 4, and 8 weeks after injections. In addition, a home diary recording any change in headache severity was kept by each patient. BTX-A treatment resulted in significant decrease of the total tenderness score, obtained by the palpation method, one week, 2 weeks, 4 weeks, as well as 8 weeks after injection. Placebo had no effect. According to patients` diaries the severity and the duration of the attacks decreased significantly during BTX-A treatment period. This is the first double-blind study that suggests that BTX-A is safe and effective substance in the treatment of patients with TTH.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti